Travere Therapeutics Inc
NASDAQ:TVTX
Intrinsic Value
Travere Therapeutics, Inc. is a biopharmaceutical company. [ Read More ]
The intrinsic value of one
TVTX
stock under the Base Case scenario is
31.04
USD.
Compared to the current market price of 5.45 USD,
Travere Therapeutics Inc
is
Undervalued by 82%.
Travere Therapeutics Inc's market capitalization is 410.8m USD.
TVTX stock price is 5.45 USD.
TVTX stock price (5.45 USD) is 82% less than its Intrinsic Value (31.04 USD).
TVTX. Open DCF Valuation
TVTX stock price (5.45 USD) is 82% less than its Relative Value (31.04 USD). Open Relative Valuation
TVTX has upside potential of 177% compared to the average analyst price target.
Open Wall St Estimates
TVTX's long-term assets (789m USD) exceed its long-term liabilties (588m USD).
TVTX's ROE (Return on Equity) has significantly decreased in the last 3 years from -76% to -91%, and is approaching profitability.
TVTX's Revenue has been falling by 10% per year for the last 3 years.
TVTX's Revenue has dropped by 31% over the past 12 months.
TVTX's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -96% to -196%, and is approaching profitability.
TVTX has negative Net Debt. This means that the company has more cash and short-term investments (567m USD) than debt (377m USD).
TVTX's D/E (Debt to Equity) is equal to 1.88.
TVTX has negative Operating Income for the last twelve months.
TVTX has negative Net Income for the last twelve months.
TVTX's ROE (Return on Equity) for the past 12 months is negative and is equal to -91%.
TVTX's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -196%.
TVTX's Revenue is forecast to grow at a rate of 45% per year over the next 3 years.
TVTX has positive Gross Profit for the last twelve months.
TVTX has negative Free Cash Flow for the last twelve months.
TVTX's short-term assets (617m USD) exceed its short-term liabilties (178m USD).
TVTX has negative three-year average ROE (Return on Equity): -103%. The company is not efficient at transforming stockholders' equity into net income.
TVTX has negative three-year average ROIC (Return on Invested Capital): -120%. The company is not efficient at using invested capital to generate operating income.
TVTX's Altman Z-Score is very low and is equal to -2.89.
TVTX doesn't generate enough operating income (-377m USD) to safely cover interest payments on its debt (9m USD).
Valuation Backtest
Travere Therapeutics Inc
Run backtest to discover the historical profit from buying and selling
TVTX
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Travere Therapeutics Inc
Balance Sheet Decomposition
Travere Therapeutics Inc
| Current Assets | 616.8m |
| Cash & Short-Term Investments | 566.9m |
| Receivables | 21.2m |
| Other Current Assets | 28.7m |
| Non-Current Assets | 172.1m |
| PP&E | 25.5m |
| Intangibles | 104.4m |
| Other Non-Current Assets | 42.2m |
| Current Liabilities | 177.9m |
| Accounts Payable | 41.7m |
| Accrued Liabilities | 97.9m |
| Other Current Liabilities | 38.3m |
| Non-Current Liabilities | 410.2m |
| Long-Term Debt | 377.3m |
| Other Non-Current Liabilities | 32.9m |
Earnings Waterfall
Travere Therapeutics Inc
|
Revenue
|
145.2m
USD
|
|
Cost of Revenue
|
-11.5m
USD
|
|
Gross Profit
|
133.8m
USD
|
|
Operating Expenses
|
-510.5m
USD
|
|
Operating Income
|
-376.7m
USD
|
|
Other Expenses
|
265.3m
USD
|
|
Net Income
|
-111.4m
USD
|
Free Cash Flow Analysis
Travere Therapeutics Inc
TVTX Profitability Score
Profitability Due Diligence
Travere Therapeutics Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
Score
Travere Therapeutics Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
TVTX Solvency Score
Solvency Due Diligence
Travere Therapeutics Inc's solvency score is 35/100. The higher the solvency score, the more solvent the company is.
Score
Travere Therapeutics Inc's solvency score is 35/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
TVTX Price Targets Summary
Travere Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
TVTX
is 15.1 USD
with a low forecast of 9.09 USD and a high forecast of 22.05 USD.
Ownership
TVTX Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
TVTX Price
Travere Therapeutics Inc
| Average Annual Return | 11.78% |
| Standard Deviation of Annual Returns | 59% |
| Max Drawdown | -83% |
| Market Capitalization | 410.8m USD |
| Shares Outstanding | 76 098 496 |
| Percentage of Shares Shorted | 15.67% |
Company Profile
Travere Therapeutics Inc
Country
Industry
Market Cap
Dividend Yield
Description
Travere Therapeutics, Inc. is a biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 310 full-time employees. The company went IPO on 2003-07-23. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its products include Chenodal (chenodiol tablets), Cholbam (cholic acid capsules), and Thiola and Thiola EC (tiopronin tablets). Chenodal, which is for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Cholbam, which is for the treatment of bile acid synthesis disorders due to single enzyme defects. Thiola and Thiola EC, which are for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria. The firm's clinical program Sparsentan (RE-021), is an investigational product candidate with a dual mechanism of action, selective endothelin receptor antagonist (ERA), with in vitro selectivity toward endothelin receptor type A, and a potent angiotensin receptor blocker.
Contact
IPO
Employees
Officers
The intrinsic value of one
TVTX
stock under the Base Case scenario is
31.04
USD.
Compared to the current market price of 5.45 USD,
Travere Therapeutics Inc
is
Undervalued by 82%.
You don't have any saved screeners yet
